Phase 3 N=75 Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months
Immune Thrombocytopenia
Primary: Durable Platelet Response — 15; 0 Participants — p=0.0077
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=203 Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
Immune Thrombocytopenia
Primary: Percentage of Time With a Platelet Response During the First 6 Months of Treatment — 50.00 percentage of time
Phase 3 N=62 Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Percentage of Participants With a Durable Platelet Response — 10.0; 52.4 percentage of participants — p=0.0018
Phase 3 N=66 A Study Evaluating the Safety and Efficacy of Long-term Dosing of Romiplostim in Thrombocytopenic Pediatric Patients With Immune (Idiopathic) Thrombocytopenia Purpura
Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
Primary: Number of Participants With Adverse Events — 64; 19; 2; 1 Participants
Phase 2 N=22 Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric Subjects
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) · Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Adverse Events — 16; 5 Participants
Phase 3 N=122 Eltrombopag vs Standard Front Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children
Immune Thrombocytopenia
Primary: Proportion of Patients With a Platelet Response — 52; 14 Participants
Phase 3 N=92 Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1 — 1; 25 Participants…
Phase 3 N=9 A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Purpura, Thrombocytopenic, Idiopathic
Primary: Number of Participants With Adverse Events — 3; 1; 1; 1 participants
Phase 2 N=15 Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Purpura, Thrombocytopaenic, Idiopathic
Primary: Percentage of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) at Least Once, Between Day 8 and Day 43 (Weeks 1 to 6) of the Randomized Period of…
Phase 3 N=34 P3 Study to Evaluate Efficacy and Safety of AMG 531 in Thrombocytopenic Japanese Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
Idiopathic Thrombocytopenic Purpura
Primary: Weeks With Weekly Platelet Response — 0.0; 11.0 Weeks — p=<0.0001
Phase 2 N=16 Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 7; 1 Participants
Phase 2 N=41 A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia
Primary Immune Thrombocytopenia
Primary: Percentage of Participants With at Least One Grade 3 or Higher Treatment Emergent Adverse Event (TEAE), Treatment Emergent Serious Adverse Event (SAE), and TEAEs Leading…
Phase 2 N=45 Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 4; 4; 4; 4 Participants
Phase 3 N=23 Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Chronic Idiopathic Thrombocytopenic Purpura · Purpura, Thrombocytopenic, Idiopathic
Primary: Number of Responders at Week 6 — 9; 0; 6; 8 Participants
Phase 3 N=64 IGIV Study for Chronic ITP Patients Ages 3-70
Idiopathic Thrombocytopenic Purpura
Primary: Response Rate — 81.3 percentage of responders
Phase 3 N=57 Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10
Immune Thrombocytopenic Purpura
Primary: Platelet Response — 80.7 Percent of participants
Phase 3 N=407 An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenic Purpura
Primary: Adverse Events — 162; 215 participants
Phase 3 N=18 Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura
Immune (Idiopathic) Thrombocytopenic Purpura
Primary: Responder Patients — 72.2 percentage of subjects
Phase 3 N=197 RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag
Purpura, Thrombocytopaenic, Idiopathic
Primary: Percentage of Responders — 2; 1; 7; 37 Percentage of participants — p=<0.001
Phase 2 N=75 Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim
Idiopathic Thrombocytopenic Purpura
Primary: Number of Months With Platelet Response During the 12-Month Treatment Period — 9.2 months
Phase 3 N=19 Clinical Evaluation of Eltrombopag in Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Purpura · Purpura, Thrombocytopenic, Idiopathic
Primary: Number of Participants Experiencing an Adverse Event (AE) and/or Serious Adverse Event (SAE) Within the Indicated Category — 19; 6; 5; 0 participants
Phase 4 N=162 A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Purpura, Thrombocytopaenic, Idiopathic
Primary: Number of Participants With Bone Marrow (BM) Fibers of MF Grade 0, 1, 2 and 3 on the European Consensus (EC) Scale at Baseline — 150; 9; 0; 0 Participants
Phase 3 N=234 Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Number of Participants With Splenectomy During 52-Week Treatment Period — 28; 14; 49; 143 Participants — p=<0.0001
Phase 2 N=86 A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)
Immune Thrombocytopenia
Primary: Part A: Percentage of Participants Who Achieved 2 or More Consecutive Platelet Counts by Starting Dose Level and Overall — 44.4; 0.0; 40.0; 40.0 percentage of participants
Phase 3 N=19 Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP
Immune Thrombocytopenia
Primary: Cumulative Number of Weeks of Platelet Response — 13.47 cumulative number of weeks
Phase 3 N=313 Open Label Extension Study of Romiplostim (AMG 531) in Thrombocytopenic Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Thrombocytopenia · Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants With Adverse Events — 284; 19 Participants
N/A N=326 Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Idiopathic Thrombocytopenic Purpura · Thrombocytopenia · Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
Primary: Number of Participants Utilizing Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Therapies for First-line Treatment — 128; 37; 3; 11 Participants
Phase 3 N=26 Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia
Purpura, Thrombocytopenic, Idiopathic
Primary: Remission Duration — 3; 11 Participants
Phase 2 N=66 Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia
Thrombocytopenia
Primary: Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (TEAE) During the Study — 80.0; 60.0; 58.3; 91.7 percentage of participants
Phase 3 N=123 Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
Immune Thrombocytopenic Purpura
Primary: Percentage of Subjects Who Achieved Platelet Count of at Least 50,000/µL Within 12 Weeks of Beginning Treatment up to 12 Months (Fostamatinib in 047/048 or 049):Version…